Leflunomide in Previously Treated Metastatic Triple Negative Cancers
Phase 1/2 Completed
17 enrolled
Study of DF1001 in Patients With Advanced Solid Tumors
Phase 1/2 Completed
270 enrolled
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Phase 1/2 Completed
50 enrolled 12 charts
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Phase 1/2 Completed
215 enrolled 30 charts
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
Phase 1/2 Completed
15 enrolled 18 charts
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Phase 1/2 Completed
185 enrolled 23 charts
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
Phase 1/2 Completed
43 enrolled 15 charts
HIT
Phase 1/2 Completed
34 enrolled
MORPHEUS HR+BC
Phase 1/2 Completed
144 enrolled 25 charts
Study of ESG401 in Adults With Solid Tumors
Phase 1/2 Completed
156 enrolled
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Phase 1/2 Completed
153 enrolled
GLIMMER-01
Phase 1/2 Completed
69 enrolled 13 charts
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
Study to Evaluate CCS1477 in Advanced Tumours
Phase 1/2 Completed
220 enrolled
NTproBNP-Guide
Phase 1/2 Completed
101 enrolled
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
Phase 1/2 Completed
23 enrolled 14 charts
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
Phase 1/2 Completed
84 enrolled
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
Phase 1/2 Completed
6 enrolled 4 charts
MAGSNOW
Phase 1/2 Completed
50 enrolled
IT-01
Phase 1/2 Completed
111 enrolled 21 charts
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
Phase 1/2 Completed
15 enrolled 11 charts
Karisma-1
Phase 1/2 Completed
42 enrolled 6 charts
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
Phase 1/2 Completed
128 enrolled 36 charts
Compare
Phase 1/2 Completed
143 enrolled 23 charts
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
Phase 1/2 Completed
323 enrolled
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
Phase 1/2 Completed
132 enrolled
MOVIE
Phase 1/2 Completed
126 enrolled
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Phase 1/2 Completed
71 enrolled 15 charts
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
Phase 1/2 Completed
58 enrolled
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1/2 Completed
169 enrolled
Novel Preventive Approach Against Filgrastim-Induced Bone Pain in Cancer Patients
Phase 1/2 Completed
58 enrolled
Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT
Phase 1/2 Completed
13 enrolled
Dendritic Cell Vaccination for Patients with Solid Tumors
Phase 1/2 Completed
48 enrolled
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
Phase 1/2 Completed
71 enrolled
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Phase 1/2 Completed
89 enrolled 16 charts
B-IMMUNE
Phase 1/2 Completed
57 enrolled
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Phase 1/2 Completed
26 enrolled 14 charts
APBI Proton Feasibility and Phase II Study
Phase 1/2 Completed
40 enrolled 6 charts
Vaccination of High Risk Breast Cancer Patients
Phase 1/2 Completed
58 enrolled 27 charts
Vaccination of Triple Negative Breast Cancer Patients
Phase 1/2 Completed
16 enrolled 30 charts
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
Phase 1/2 Completed
182 enrolled 37 charts
Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors
Phase 1/2 Completed
3 enrolled
CANFOUR
Phase 1/2 Completed
167 enrolled
A Study of ZN-c5 in Subjects With Breast Cancer
Phase 1/2 Completed
181 enrolled 36 charts
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
Phase 1/2 Completed
22 enrolled 10 charts
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
Phase 1/2 Completed
203 enrolled
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Completed
109 enrolled 25 charts
KEYNOTE-899
Phase 1/2 Completed
84 enrolled
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
Phase 1/2 Completed
28 enrolled 12 charts
STESIDES
Phase 1/2 Completed
38 enrolled